MCID: KPS004
MIFTS: 73

Kaposi Sarcoma

Categories: Genetic diseases, Rare diseases, Cancer diseases, Cardiovascular diseases, Fetal diseases, Blood diseases

Aliases & Classifications for Kaposi Sarcoma

MalaCards integrated aliases for Kaposi Sarcoma:

Name: Kaposi Sarcoma 57 12 76 53 59 55 43 73
Kaposi's Sarcoma 12 53 37 29 15
Kaposi Sarcoma, Susceptibility to 57 13 6
Angiofollicular Ganglionic Hyperplasia 59 73
Kaposi's Sarcoma of Soft Tissue 12 73
Kaposi's Sarcoma of Palate 12 73
Kaposi's Sarcoma of Lung 12 73
Multiple Idiopathic Pigmented Hemangiosarcoma, Susceptibility to 57
Multiple Idiopathic Pigmented Hemangiosarcoma 57
Kaposi's Sarcoma of Central Nervous System 12
Kaposi's Sarcoma of Gastrointestinal Sites 12
Multicentric Giant Lymph Node Hyperplasia 59
African Lymphadenopathic Kaposi's Sarcoma 12
Central Nervous System Kaposi's Sarcoma 12
Kaposi's Sarcoma-Associated Herpesvirus 12
Kaposi's Sarcoma of the Gallbladder 12
Sarcoma, Kaposi, Susceptibility to 40
Angiofollicular Lymph Hyperplasia 59
Lymphadenopathic Kaposi's Sarcoma 12
Multi-Centric Castleman's Disease 73
Kaposi's Sarcoma of Soft Tissues 12
Kaposi's Sarcoma of the Prostate 12
Kaposi's Sarcoma of Conjunctiva 12
Kaposi's Sarcoma of Lymph Nodes 12
Non Aids Related Kaposi Sarcoma 53
Non-Aids-Related Kaposi Sarcoma 73
Multicentric Castleman Disease 59
Conjunctival Kaposi's Sarcoma 12
Kaposi's Sarcoma of Esophagus 12
Gallbladder Kaposi's Sarcoma 12
Soft Tissue Kaposi's Sarcoma 12
Mediterranean Kaposi Sarcoma 53
Esophageal Kaposi's Sarcoma 12
Intestinal Kaposi's Sarcoma 12
Kaposi's Sarcoma of the Cns 12
Lymph Node Kaposi's Sarcoma 12
Cutaneous Kaposi's Sarcoma 12
Kaposi's Sarcoma of Cornea 12
Pulmonary Kaposi's Sarcoma 12
Kaposi Sarcoma Herpesvirus 53
Kaposi's Sarcoma of Heart 12
Kaposi's Sarcoma of Penis 12
Prostate Kaposi's Sarcoma 12
Angiolymphoid Hyperplasia 73
Cardiac Kaposi's Sarcoma 12
Corneal Kaposi's Sarcoma 12
Gastric Kaposi's Sarcoma 12
Kaposi's Sarcoma of Anus 12
Kaposi's Sarcoma of Skin 12
Palate Kaposi's Sarcoma 12
Kaposi's Sarcoma, Lung 12
Kaposi's Sarcoma, Skin 12
Penis Kaposi's Sarcoma 12
Anal Kaposi's Sarcoma 12
Human Herpesvirus 8 53
Castleman Disease 59
Sarcoma, Kaposi 44
Hhv8 53
Kshv 53
Mcd 59

Characteristics:

Orphanet epidemiological data:

59
kaposi sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult;
castleman disease
Inheritance: Not applicable; Age of onset: All ages;

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
kaposi sarcoma:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Kaposi Sarcoma

NIH Rare Diseases : 53 Kaposi sarcoma (KS) is a cancer that develops from the cells that line lymph or blood vessels. It usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but tumors can also develop in other parts of the body (including the lymph nodes, lungs, or digestive tract). The abnormal cells of Kaposi sarcoma cause purplish, reddish blue, or dark brown/black skin lesions (macules, nodules, plaques) on the legs and the face. These lesions may look bad, but they usually cause no symptoms. However, when the lesions are in the lungs, liver, or digestive tract, they may cause serious problems like gastrointestinal bleeding or trouble breathing. Kaposi sarcoma is caused by infection with a virus called the Kaposi sarcoma associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8). Kaposi sarcoma is classified into four types based upon the different populations in which it develops: classic (which presents in middle or old age), endemic (described in sub-Saharan indigenous Africans), iatrogenic (associated with immunosuppressive drug therapy) and AIDS-associated (epidemic KS). Options for treatment may include local therapy, radiation therapy, chemotherapy and biologic therapy (immunotherapy). The main aim is to restore immunity.

MalaCards based summary : Kaposi Sarcoma, also known as kaposi's sarcoma, is related to hepatitis and hepatitis c, and has symptoms including exanthema, pruritus and fever. An important gene associated with Kaposi Sarcoma is IL6 (Interleukin 6), and among its related pathways/superpathways are Kaposi's sarcoma-associated herpesvirus infection and Viral carcinogenesis. The drugs Doxil and Intron A have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and lung, and related phenotypes are fever and fatigue

OMIM : 57 Kaposi sarcoma (KS) is an invasive angioproliferative inflammatory condition that occurs commonly in men infected with human immunodeficiency virus (HIV; see 609423). In the early stages of KS, lesions appear reactive and are stimulated to grow by the actions of inflammatory cytokines and growth factors. In the late stages of KS, a malignant phenotype that appears to be monoclonal can develop. Infection with human herpesvirus-8 (HHV-8), also known as KS-associated herpesvirus (KSHV), is necessary but not sufficient for KS development. Coinfection with HIV markedly increases the likelihood of KS development, and additional environmental, hormonal, and genetic cofactors likely contribute to its pathogenesis (summary by Foster et al., 2000). Suthaus et al. (2012) noted that HHV-8 is the etiologic agent not only of KS, but also of primary effusion lymphoma and plasma cell-type multicentric Castleman disease (MCD). (148000)

MedlinePlus : 43 Kaposi sarcoma (KS) is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat, in lymph nodes, or in other organs. These patches, or lesions, are usually red or purple. They are made of cancer cells, blood vessels, and blood cells. KS is caused by infection with human herpesvirus-8 (HHV-8). Most people infected with HHV-8 don't get KS. It usually happens in People with weak immune systems, due to HIV/AIDS, drugs taken after an organ transplant, or another disease Older men of Jewish or Mediterranean descent Young men in Africa The skin lesions may not cause symptoms. But they can spread to other parts of the body, especially in people with HIV/AIDS. If they spread to the digestive tract or lungs, they can cause bleeding. Lesions on the lungs can also make it hard to breathe. Treatment depends on where the lesions are and how bad they are. Options include radiation therapy, surgery, chemotherapy, and biologic therapy. People with HIV/AIDS also take HIV/AIDS Medicines. NIH: National Cancer Institute

Disease Ontology : 12 A connective tissue cancer that derives from lymphatic endothelium, and derives from spindle cells, results in_formation_of vascular channels that fill with blood cells, has material basis in Human herpesvirus 8 (HHV8).

Wikipedia : 76 Kaposi\'s sarcoma (KS) is a type of cancer that can form masses in the skin, lymph nodes, or other... more...

Related Diseases for Kaposi Sarcoma

Diseases related to Kaposi Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 159)
# Related Disease Score Top Affiliating Genes
1 hepatitis 30.9 IFNA1 IFNA2 IRF3 IRF7
2 hepatitis c 30.1 IFNA1 IFNA2 IFNB1 IRF3 IRF7
3 molluscum contagiosum 29.7 CASP8 CCR8 IFNB1
4 human immunodeficiency virus type 1 28.5 CASP8 CCR3 IFNA1 IL6 IRF3
5 endemic kaposi sarcoma 12.3
6 colon kaposi sarcoma 12.1
7 immunodeficiency 16 12.0
8 human herpesvirus 8 11.9
9 malonyl-coa decarboxylase deficiency 11.8
10 rectum kaposi's sarcoma 11.1
11 plantar wart 11.1 IFNA1 TP53
12 sarcoma 11.0
13 macular retinal edema 11.0 ICAM1 IL6 VEGFA
14 oral erosive lichen 11.0 IFNA1 IFNB1
15 lymphomatoid granulomatosis 11.0 IFNA1 IFNA2
16 pericardial effusion 11.0 FGF2 IL6 VEGFA
17 limb ischemia 10.9 FGF2 IL6 VEGFA
18 breast carcinoma in situ 10.9 IL6ST TP53 VEGFA
19 squamous papillomatosis 10.9 IFNA1 IFNA2
20 microvascular complications of diabetes 1 10.9 FGF2 ICAM1 VEGFA
21 sleep apnea 10.9 ICAM1 IL6 VEGFA
22 endometrial adenocarcinoma 10.9 FGF2 TP53 VEGFA
23 diabetic macular edema 10.8 FGF2 ICAM1 IL6 VEGFA
24 melanoma, cutaneous malignant 1 10.8 CDK6 IFNA2 TP53
25 microvascular complications of diabetes 5 10.8 FGF2 ICAM1 VEGFA
26 bone marrow cancer 10.8 FGF2 IFNA1 IFNA2 IL6
27 arteries, anomalies of 10.8 ICAM1 IL6 VEGFA
28 critical limb ischemia 10.8 IL6 VEGFA
29 mouth disease 10.7 IFNA1 IL6 IRF3
30 gastrointestinal system cancer 10.7 IL6 TP53 VEGFA
31 severe acute respiratory syndrome 10.7 IFNA1 IFNB1 IRF3
32 relapsing-remitting multiple sclerosis 10.7 ICAM1 IFNA1 IFNB1
33 cryoglobulinemia, familial mixed 10.6 IFNA1 IFNA2
34 squamous cell carcinoma, head and neck 10.6 CDK6 FGF2 TP53 VEGFA
35 newcastle disease 10.5 IFNA1 IFNB1 IRF3 IRF7
36 vascular disease 10.5 FGF2 ICAM1 IL6 VEGFA
37 polyarteritis nodosa 10.5 ADA2 IFNA2 IL6
38 vitreous disease 10.5 FGF2 PDGFB VEGFA
39 conjunctival squamous cell carcinoma 10.4 IFNA2 TP53
40 renal cell carcinoma, nonpapillary 10.4 FGF2 IFNA1 IFNA2 VEGFA
41 lymphoma 10.4
42 influenza 10.4 IFNA1 IFNB1 IRF3 IRF7
43 diabetic foot ulcers 10.4 IL6 PDGFB
44 demyelinating disease 10.4 ICAM1 IFNA1 IFNB1
45 multicentric castleman disease 10.4
46 castleman disease 10.4
47 adult hepatocellular carcinoma 10.4 CASP8 TP53
48 connective tissue cancer 10.3 FGF2 PDGFB TP53 VEGFA
49 behcet syndrome 10.3 ADA2 IFNA1 IFNA2 IL6
50 primary effusion lymphoma 10.3

Graphical network of the top 20 diseases related to Kaposi Sarcoma:



Diseases related to Kaposi Sarcoma

Symptoms & Phenotypes for Kaposi Sarcoma

Symptoms via clinical synopsis from OMIM:

57
Oncology:
kaposi sarcoma

Misc:
rarely familial

Skin:
red-purple nodules, plaques, and macules
limb edema


Clinical features from OMIM:

148000

Human phenotypes related to Kaposi Sarcoma:

59 32 (show all 29)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 59 32 occasional (7.5%) Occasional (29-5%) HP:0001945
2 fatigue 59 32 occasional (7.5%) Occasional (29-5%) HP:0012378
3 immunodeficiency 59 32 frequent (33%) Frequent (79-30%) HP:0002721
4 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
5 lymphedema 59 32 occasional (7.5%) Occasional (29-5%) HP:0001004
6 abnormality of the spleen 59 32 frequent (33%) Frequent (79-30%) HP:0001743
7 neoplasm of the skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0008069
8 diarrhea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002014
9 skin rash 59 32 occasional (7.5%) Occasional (29-5%) HP:0000988
10 venous insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0005293
11 hypermelanotic macule 59 32 hallmark (90%) Very frequent (99-80%) HP:0001034
12 papule 59 32 frequent (33%) Frequent (79-30%) HP:0200034
13 abnormality of the gastrointestinal tract 59 32 frequent (33%) Frequent (79-30%) HP:0011024
14 abnormality of the liver 59 32 occasional (7.5%) Occasional (29-5%) HP:0001392
15 encephalopathy 59 32 frequent (33%) Frequent (79-30%) HP:0001298
16 abnormality of the lower limb 59 32 hallmark (90%) Very frequent (99-80%) HP:0002814
17 abnormal retinal morphology 59 32 frequent (33%) Frequent (79-30%) HP:0000479
18 skin nodule 59 32 frequent (33%) Frequent (79-30%) HP:0200036
19 skin plaque 59 32 occasional (7.5%) Occasional (29-5%) HP:0200035
20 hemangioma 59 32 frequent (33%) Frequent (79-30%) HP:0001028
21 lymphoproliferative disorder 59 32 frequent (33%) Frequent (79-30%) HP:0005523
22 generalized lymphadenopathy 59 32 frequent (33%) Frequent (79-30%) HP:0008940
23 susceptibility to herpesvirus 59 32 obligate (100%) Obligate (100%) HP:0005353
24 neoplasm 32 HP:0002664
25 edema 32 HP:0000969
26 macule 59 Very frequent (99-80%)
27 abnormality of lung morphology 59 Occasional (29-5%)
28 neoplasm by anatomical site 59 Occasional (29-5%)
29 abnormal lung morphology 32 occasional (7.5%) HP:0002088

UMLS symptoms related to Kaposi Sarcoma:


exanthema, pruritus, fever

MGI Mouse Phenotypes related to Kaposi Sarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.27 SLC7A11 TP53 VEGFA CASP8 CCR3 CDK6
2 cellular MP:0005384 10.26 CASP8 CCR3 CDK6 FGF2 FGF4 ICAM1
3 homeostasis/metabolism MP:0005376 10.25 CASP8 CCR3 FGF2 ICAM1 IFNB1 IL6
4 immune system MP:0005387 10.25 CASP8 CCR3 CCR8 CDK6 ICAM1 IFNB1
5 integument MP:0010771 9.97 CASP8 ICAM1 IL6 IL6ST PDGFB SLC7A11
6 liver/biliary system MP:0005370 9.87 CDK6 IL6 IL6ST PDGFB TP53 VEGFA
7 muscle MP:0005369 9.86 CASP8 CDK6 FGF2 ICAM1 IL6 PDGFB
8 neoplasm MP:0002006 9.85 IL6 IL6ST SLC7A11 TP53 VEGFA CASP8
9 respiratory system MP:0005388 9.5 CASP8 CCR3 FGF4 IL6 PDGFB TP53
10 vision/eye MP:0005391 9.23 FGF2 ICAM1 IL6 IL6ST PDGFB SLC7A11

Drugs & Therapeutics for Kaposi Sarcoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Doxil 18 49 DOXORUBICIN HYDROCHLORIDE Alza June 1999
2
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
3
Taxol 18 49 PACLITAXEL Bristol-Myers Squibb August 1997

Drugs for Kaposi Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bleomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
4
Efavirenz Approved, Investigational Phase 4,Phase 3,Not Applicable 154598-52-4 64139
5
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 155213-67-5 392622
6
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 134678-17-4 60825
7
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
8
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
9
Emtricitabine Approved, Investigational Phase 4,Phase 3,Not Applicable 143491-57-0 60877
10
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
11
Ganciclovir Approved, Investigational Phase 4,Phase 2,Not Applicable 82410-32-0 3454
12
Valganciclovir Approved, Investigational Phase 4,Phase 2,Not Applicable 175865-60-8 64147
13
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
14 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
15 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
16 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
17 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
18 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
19
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
20 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
21 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Not Applicable
22 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
23 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Not Applicable
25 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
26 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
27 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4,Phase 3
28
Tenofovir Phase 4,Phase 3,Not Applicable 147127-20-6 464205
29 Atazanavir Sulfate Phase 4,Phase 3
30 Ganciclovir triphosphate Phase 4,Phase 2,Not Applicable
31
Meloxicam Approved, Vet_approved Phase 3 71125-38-7 5281106 54677470
32
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
33
Abacavir Approved, Investigational Phase 2, Phase 3 136470-78-5 65140 441300
34
Zidovudine Approved Phase 2, Phase 3,Phase 3,Phase 1 30516-87-1 35370
35
Daunorubicin Approved Phase 3,Phase 1 20830-81-3 30323
36
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
37
Aldesleukin Approved Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
38
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
39
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
40
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
41 tannic acid Approved, Nutraceutical Phase 3
42 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
43 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
44 Antimitotic Agents Phase 3,Phase 2,Phase 1
45 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
46 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
47 Analgesics Phase 3,Phase 2,Phase 1,Not Applicable
48 Analgesics, Non-Narcotic Phase 3,Phase 2,Phase 1,Not Applicable
49 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 180)
# Name Status NCT ID Phase Drugs
1 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
2 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
3 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
4 Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease Withdrawn NCT00361933 Phase 4 Valganciclovir
5 A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
6 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
7 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir
8 Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma Completed NCT00003350 Phase 3 paclitaxel;pegylated liposomal doxorubicin hydrochloride
9 Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
10 A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3 Doxorubicin hydrochloride (liposomal)
11 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3 Doxorubicin hydrochloride (liposomal)
12 Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients Completed NCT00002445 Phase 3 IM862
13 A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00000994 Phase 3 Zidovudine
14 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002105 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate
15 A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. Completed NCT00002093 Phase 3 Daunorubicin (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
16 Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS Completed NCT01435018 Phase 3 Coformulated EFV/FTC/TDF;Etoposide;Bleomycin and Vincristine (BV);Paclitaxel (PTX)
17 PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV) Completed NCT01099579 Phase 3 Atazanavir powder;Ritonavir oral solution;Atazanavir capsules;Ritonavir capsules
18 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) Completed NCT00013611 Phase 3 Proleukin
19 Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone Completed NCT01924286 Phase 3 Prednisone;Placebo
20 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
21 Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) Recruiting NCT03092817 Phase 3 Dexamethasone
22 Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma Active, not recruiting NCT01352117 Phase 3 efavirenz/emtricitabine/tenofovir disoproxil fumarate;etoposide
23 Antiviral Therapy in Treating Patients With Slowly Progressing HIV-Related Kaposi's Sarcoma Unknown status NCT00003419 Phase 2
24 Phase II Multicentric Study of Digoxin Per os in Classic or Endemic Kaposi' s Sarcoma Unknown status NCT02212639 Phase 2 digoxin
25 Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer Unknown status NCT00622466 Phase 2 paclitaxel;sorafenib tosylate
26 Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma Completed NCT01067690 Phase 2 Indinavir in association with Vinblastina +/- Bleomicina
27 Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity Completed NCT01296815 Phase 2 Bevacizumab
28 Treatment of Classical Non-HIV-Related Kaposi's Sarcoma With the Antiviral Drug Indinavir Completed NCT00362310 Phase 2 indinavir
29 Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT01057121 Phase 1, Phase 2 Lenalidomide
30 Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00019188 Phase 1, Phase 2 interleukin-12
31 Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00064142 Phase 2 halofuginone hydrobromide
32 A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma Completed NCT02029430 Phase 2 aldoxorubicin
33 Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients Completed NCT00055237 Phase 2
34 Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT Completed NCT02201420 Phase 2 Tc 99m tilmanocept
35 Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma Completed NCT00295984 Phase 2 nicotine
36 Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00090987 Phase 2 imatinib mesylate
37 BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00024024 Phase 1, Phase 2 rebimastat
38 SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00005042 Phase 2 semaxanib
39 Suppression of Oral HHV8 Shedding With Valganciclovir Completed NCT00194467 Phase 2 valganciclovir;placebo
40 Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma Completed NCT00019123 Phase 2 thalidomide
41 Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV Infection Completed NCT00019240 Phase 2 cidofovir
42 Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00003008 Phase 2 indinavir sulfate;nelfinavir mesylate;paclitaxel;ritonavir;saquinavir mesylate
43 Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00020449 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
44 A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002188 Phase 2 Alitretinoin
45 A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma Completed NCT00002131 Phase 2 Vesnarinone
46 A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002212 Phase 2 Bexarotene
47 The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma Completed NCT00002366 Phase 2 Ritonavir
48 Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma Completed NCT00002259 Phase 2 Mitoxantrone hydrochloride
49 SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment Completed NCT00005931 Phase 2 SU5416
50 The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma Completed NCT00001114 Phase 2 Interferon alfa-2b;Didanosine

Search NIH Clinical Center for Kaposi Sarcoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: sarcoma, kaposi

Genetic Tests for Kaposi Sarcoma

Genetic tests related to Kaposi Sarcoma:

# Genetic test Affiliating Genes
1 Kaposi's Sarcoma 29 IL6

Anatomical Context for Kaposi Sarcoma

MalaCards organs/tissues related to Kaposi Sarcoma:

41
Skin, Lymph Node, Lung, Prostate, Liver, Heart, Testes

Publications for Kaposi Sarcoma

Articles related to Kaposi Sarcoma:

(show top 50) (show all 428)
# Title Authors Year
1
Kaposi Sarcoma in the Era of Rapamycin Remains a Therapeutic Challenge in Organ Transplant Recipients. ( 29527986 )
2018
2
Evolution of Kaposi sarcoma in the past 30A years in a tertiary hospital of the European Mediterranean basin. ( 29934954 )
2018
3
Case of classic Kaposi sarcoma of the penis successfully treated with radiotherapy. ( 29341256 )
2018
4
PD-1 blockade with nivolumab in endemic Kaposi sarcoma. ( 29324995 )
2018
5
Role of Radiotherapy in Mucosal Kaposi Sarcoma. ( 29383006 )
2018
6
Kaposi Sarcoma With Coexisting Intravascular Lymphoma. ( 29532696 )
2018
7
Membrane-Associated Kaposi Sarcoma-Associated Herpesvirus Glycoprotein B Promotes Cell Adhesion and Inhibits Migration of Cells via Upregulating IL-1I^ and TNF-I+. ( 29597230 )
2018
8
A case of recipient-derived pulmonary Kaposi sarcoma after bilateral lung transplantation. ( 29793656 )
2018
9
Kaposi Sarcoma of the Ear in HIV-Negative Patients. ( 29671213 )
2018
10
Kaposi sarcoma presenting shortly after primary infection by HIV and human herpesvirus-8. ( 29256918 )
2018
11
Kaposi sarcoma in an immunosuppressed young woman. ( 29398005 )
2018
12
Topical timolol for Kaposi sarcoma: An innovation. ( 29624656 )
2018
13
First application of hemi-body electron beam irradiation for Kaposi sarcoma at the lower extremities. ( 29552795 )
2018
14
Pseudo-Kaposi sarcoma: report of a case investigated by dermoscopy, reflectance confocal microscopy and optical coherence tomography. ( 29729117 )
2018
15
Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease. ( 29157621 )
2018
16
Recommendations for Counseling and Education of Service Members on Endemic African Cutaneous Kaposi Sarcoma: A Case Study. ( 29590438 )
2018
17
Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma. ( 29797733 )
2018
18
Eyelid Kaposi Sarcoma in an HIV-negative Patient. ( 29786002 )
2018
19
Kaposi Sarcoma After Allogeneic Hematopoietic Stem Cell Transplant: A Rare Complication. ( 29292681 )
2018
20
Age of Infection with Kaposi Sarcoma Associated Herpesvirus and Subsequent Antibody Values Among Children in Uganda. ( 29369149 )
2018
21
Relationship between Anaemia, Malaria Co-infection and Kaposi Sarcoma-associated Herpesvirus (KSHV) Seropositivity in a Population-based Study in Rural Uganda. ( 29741631 )
2018
22
Exploring the Role of IL-32 in HIV-Related Kaposi Sarcoma. ( 29037857 )
2018
23
Epidemiology of Kaposi sarcoma: review and description of the nonepidemic variant. ( 29888407 )
2018
24
Kaposi sarcoma of the upper eyelid: a rare occurrence. ( 29888854 )
2018
25
Disseminated Kaposi sarcoma with epithelioid morphology in an HIV/AIDS patient: A previously unreported variant. ( 29660143 )
2018
26
Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away. Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy. ( 29282751 )
2018
27
The Kaposi Sarcoma Herpesvirus non-structural membrane protein pK15 recruits the class II PI3K Phosphatidylinositol 4-phosphate 3-kinase C2 alpha to activate productive viral replication. ( 29950425 )
2018
28
As-Needed versus Immediate Etoposide Chemotherapy in Combination with Antiretroviral Therapy for Mild or Moderate AIDS-associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. ( 29365083 )
2018
29
Rubbery purple and red lesions in the GI tract: A Case of GI tract Kaposi Sarcoma. ( 29306041 )
2018
30
Pediatric Kaposi sarcoma in context of the HIV epidemic in sub-Saharan Africa: current perspectives. ( 29722363 )
2018
31
Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS): A Rare but Potentially Treatable Condition. ( 28424322 )
2017
32
mTOR, VEGF, PDGFR, and c-kit signaling pathway activation in Kaposi Sarcoma. ( 28506734 )
2017
33
Pulmonary Kaposi sarcoma presenting as complete lung consolidation. ( 28331023 )
2017
34
Experience with Kaposi Sarcoma Herpesvirus Inflammatory Cytokine Syndrome in a Large Urban HIV Clinic in the United States: Case Series and Literature Review. ( 29766014 )
2017
35
A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. ( 28341759 )
2017
36
Associations of CD4+ T-cell count, HIV-1 RNA viral load, and antiretroviral therapy with Kaposi sarcoma risk among HIV-infected persons in the United States and Canada. ( 28394855 )
2017
37
Kaposi Sarcoma in an Human Immunodeficiency Virus (HIV)-Seronegative Mediterranean Female: Report of a Rare Case. ( 28743856 )
2017
38
Disparities in Kaposi sarcoma incidence and survival in the United States: 2000-2013. ( 28829790 )
2017
39
Change in Pattern of Secondary Cancers After Kaposi Sarcoma in the Era of Antiretroviral Therapy. ( 28837714 )
2017
40
Oral Localization of Kaposi Sarcoma: Clinical Presentation and Conservative Management. ( 28708648 )
2017
41
Murine Gammaherpesvirus 68 Expressing Kaposi Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen (LANA) Reveals both Functional Conservation and Divergence in LANA Homologs. ( 28747501 )
2017
42
HHV8 genotype study in an HIV+ patient with concurrent Kaposi sarcoma and extracavitary primary effusion lymphoma. ( 28705937 )
2017
43
A case report of iatrogenic cutaneous Kaposi sarcoma due to rituximab therapy for thrombotic thrombocytopenic purpura. ( 27885868 )
2017
44
Plantar Kaposi Sarcoma Revealed by Antisynthetase Syndrome. ( 29239932 )
2017
45
Successful Treatment of Kaposi Sarcoma-Associated Herpesvirus Inflammatory Cytokine Syndrome After Kidney-Liver Transplant: Correlations With the Human Herpesvirus 8 miRNome and Specific T Cell Response. ( 28489271 )
2017
46
Acral pseudolymphomatous angiokeratoma of children with rainbow pattern: A mimicker of Kaposi sarcoma. ( 28087020 )
2017
47
Classic Kaposi Sarcoma: An Exceptional Cause of Adrenal Incidentaloma. ( 29264526 )
2017
48
Classic and HIV-related Kaposi sarcoma treated with 0.1% topical timolol gel. ( 27986137 )
2017
49
Oral Kaposi Sarcoma in HIV-seronegative Saudi patient: Literature review and case report. ( 28725131 )
2017
50
Hepatic Kaposi sarcoma: A case report and review of the literature. ( 28217255 )
2017

Variations for Kaposi Sarcoma

ClinVar genetic disease variations for Kaposi Sarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 IL6 IL6, -174G-C single nucleotide variant risk factor

Cosmic variations for Kaposi Sarcoma:

9
(show all 29)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM575 NRAS soft tissue,skin,sarcoma,NS c.38G>C p.G13A 1:114716123-114716123 69
2 COSM6979022 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 68
3 COSM389868 RAC1 soft tissue,lung,sarcoma,NS c.476C>T p.A159V 7:6402343-6402343 68
4 COSM6979014 PTPRD soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 68
5 COSM6959031 PTCH1 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 68
6 COSM6979006 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 68
7 COSM6979021 PAK5 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 68
8 COSM520 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 68
9 COSM516 KRAS soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 68
10 COSM6979011 HGF soft tissue,lung,sarcoma,NS c.1711G>T p.V571L 7:81706333-81706333 68
11 COSM6959034 GPS2 soft tissue,lung,sarcoma,NS c.454C>T p.Q152* 17:7313932-7313932 68
12 COSM6979008 FOXP1 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 68
13 COSM6959030 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 68
14 COSM6979007 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 68
15 COSM6979005 soft tissue,lung,sarcoma,NS c.2738G>A p.R913H 3:52589201-52589201 68
16 COSM6979012 soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 68
17 COSM6979020 soft tissue,lung,sarcoma,NS c.1831+1G>T p.? 19:45353082-45353082 68
18 COSM1140136 soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 68
19 COSM6979017 soft tissue,lung,sarcoma,NS c.2573C>T p.A858V 9:8404587-8404587 68
20 COSM6979010 soft tissue,lung,sarcoma,NS c.1036G>T p.V346L 3:179203766-179203766 68
21 COSM6979009 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 68
22 COSM1154840 soft tissue,lung,sarcoma,NS c.533C>T p.A178V 7:6402343-6402343 68
23 COSM6959033 soft tissue,lung,sarcoma,NS c.2918T>G p.F973C 9:95458260-95458260 68
24 COSM6979016 soft tissue,lung,sarcoma,NS c.2930C>T p.A977V 9:8404587-8404587 68
25 COSM6979013 soft tissue,lung,sarcoma,NS c.2942C>T p.A981V 9:8404587-8404587 68
26 COSM6959032 soft tissue,lung,sarcoma,NS c.2918T>G p.F973C 9:95458260-95458260 68
27 COSM6979015 soft tissue,lung,sarcoma,NS c.2939C>T p.A980V 9:8404587-8404587 68
28 COSM517 KRAS biliary tract,gallbladder,other,hyperplasia c.34G>A p.G12S 12:25245351-25245351 6
29 COSM521 KRAS biliary tract,gallbladder,other,hyperplasia c.35G>A p.G12D 12:25245350-25245350 6

Expression for Kaposi Sarcoma

Search GEO for disease gene expression data for Kaposi Sarcoma.

Pathways for Kaposi Sarcoma

Pathways related to Kaposi Sarcoma according to KEGG:

37
# Name Kegg Source Accession
1 Kaposi's sarcoma-associated herpesvirus infection hsa05167
2 Viral carcinogenesis hsa05203

Pathways related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 ADA2 CASP8 FGF2 FGF4 ICAM1 IFNA1
2
Show member pathways
13.87 CASP8 FGF2 FGF4 IFNA1 IFNA2 IFNB1
3
Show member pathways
13.86 CASP8 CCR3 CCR8 CDK6 FGF2 FGF4
4
Show member pathways
13.68 CASP8 CCR3 CCR8 IFNA1 IFNA2 IFNB1
5
Show member pathways
13.51 FGF2 FGF4 IFNA1 IFNA2 IFNB1 IL6
6
Show member pathways
13.4 CCR3 CCR8 FGF2 FGF4 IL6 PDGFB
7
Show member pathways
13.33 IFNA1 IFNA2 IFNB1 IRF3 IRF7 PDGFB
8
Show member pathways
13.29 CASP8 CCR3 CCR8 FGF2 FGF4 IL6
9
Show member pathways
13.18 FGF2 FGF4 ICAM1 IFNA1 IFNA2 IFNB1
10
Show member pathways
13.02 CASP8 IFNA1 IFNA2 IFNB1 IL6 IRF3
11
Show member pathways
12.88 CASP8 ICAM1 IFNA1 IFNA2 IL6 VEGFA
12 12.79 CASP8 FGF2 FGF4 PDGFB TP53 VEGFA
13
Show member pathways
12.78 CDK6 FGF2 FGF4 IL6 PDGFB TP53
14
Show member pathways
12.77 CASP8 IFNA1 IFNA2 IFNB1 IL6 IRF3
15
Show member pathways
12.71 CASP8 CDK6 ICAM1 IFNA1 IFNA2 IFNB1
16 12.62 CASP8 CDK6 FGF2 FGF4 IFNA1 IFNA2
17
Show member pathways
12.6 IFNA1 IFNA2 IFNB1 IL6 IL6ST IRF3
18
Show member pathways
12.56 ICAM1 IFNA1 IFNA2 IFNB1 IRF3 IRF7
19
Show member pathways
12.56 CASP8 CDK6 FGF2 FGF4 IFNA1 IFNA2
20 12.41 ICAM1 IL6 PDGFB TP53
21
Show member pathways
12.29 IFNA1 IFNA2 IFNB1 IL6
22 12.27 CASP8 CCR3 CCR8 CDK6 IL6ST IRF3
23 12.26 CASP8 IFNA1 IFNA2 IFNB1 IL6
24
Show member pathways
12.25 IFNB1 IL6 IRF3 IRF7
25
Show member pathways
12.2 CASP8 IFNA1 IFNA2 IFNB1
26 12.17 IFNA1 IFNA2 IFNB1 IRF3 IRF7 TP53
27 12.1 FGF2 FGF4 IL6 PDGFB VEGFA
28 12.09 ICAM1 PDGFB TP53 VEGFA
29
Show member pathways
12.08 FGF2 FGF4 ICAM1 IL6 PDGFB
30 12.07 IFNA1 IFNA2 IFNB1 IRF3 IRF7 TP53
31
Show member pathways
12.04 CASP8 CCR3 CCR8 CDK6 FGF2 ICAM1
32 11.99 FGF2 ICAM1 IL6 TP53 VEGFA
33 11.95 IFNB1 IL6 IL6ST IRF7 TP53
34 11.93 IFNA1 IFNA2 IFNB1 IL6 IL6ST
35 11.88 ICAM1 IL6 VEGFA
36
Show member pathways
11.85 ICAM1 IL6 IL6ST
37 11.83 ICAM1 IL6 VEGFA
38 11.82 FGF2 FGF4 PDGFB VEGFA
39 11.78 ICAM1 IL6 TP53
40 11.73 IFNA2 IFNB1 IL6
41 11.71 CCR3 FGF2 IL6 PDGFB
42
Show member pathways
11.65 ICAM1 IL6 VEGFA
43 11.55 IL6 TP53 VEGFA
44 11.54 FGF2 FGF4 IL6 PDGFB VEGFA
45 11.49 CASP8 FGF2 VEGFA
46 11.47 FGF2 FGF4 PDGFB VEGFA
47 11.45 CASP8 IFNA1 IFNA2 IFNB1 IL6
48 11.39 ICAM1 IFNA2 IFNB1
49 11.19 FGF2 PDGFB VEGFA
50
Show member pathways
11.17 IFNA2 IRF3 IRF7

GO Terms for Kaposi Sarcoma

Cellular components related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 ADA2 FGF2 FGF4 IFNA1 IFNA2 IFNB1
2 extracellular space GO:0005615 9.61 ADA2 FGF2 ICAM1 IFNA1 IFNA2 IFNB1
3 interleukin-6 receptor complex GO:0005896 8.62 IL6 IL6ST

Biological processes related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 FGF2 FGF4 ICAM1 PDGFB
2 viral process GO:0016032 9.95 CASP8 CCR3 ICAM1 IL6ST IRF3 IRF7
3 B cell differentiation GO:0030183 9.83 IFNA1 IFNA2 IFNB1
4 interferon-gamma-mediated signaling pathway GO:0060333 9.83 ICAM1 IRF3 IRF7
5 positive regulation of MAP kinase activity GO:0043406 9.82 FGF2 PDGFB VEGFA
6 positive regulation of blood vessel endothelial cell migration GO:0043536 9.81 FGF2 PDGFB VEGFA
7 positive regulation of endothelial cell proliferation GO:0001938 9.8 CCR3 FGF2 PDGFB VEGFA
8 positive chemotaxis GO:0050918 9.79 FGF2 PDGFB VEGFA
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.78 IFNA2 IL6 IL6ST VEGFA
10 humoral immune response GO:0006959 9.76 IFNA1 IFNA2 IFNB1 IL6
11 B cell proliferation GO:0042100 9.75 IFNA1 IFNA2 IFNB1
12 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.74 CASP8 IRF3 IRF7
13 regulation of type I interferon-mediated signaling pathway GO:0060338 9.73 IFNA1 IFNA2 IFNB1
14 positive regulation of cell division GO:0051781 9.73 FGF2 FGF4 PDGFB VEGFA
15 defense response to virus GO:0051607 9.73 IFNA1 IFNA2 IFNB1 IL6 IRF3 IRF7
16 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.72 ICAM1 IL6 PDGFB TP53 VEGFA
17 T cell activation involved in immune response GO:0002286 9.71 IFNA1 IFNA2 IFNB1
18 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.7 IFNA1 IFNA2 IFNB1
19 natural killer cell activation involved in immune response GO:0002323 9.69 IFNA1 IFNA2 IFNB1
20 cell migration involved in sprouting angiogenesis GO:0002042 9.68 FGF2 VEGFA
21 interleukin-6-mediated signaling pathway GO:0070102 9.67 IL6 IL6ST
22 positive regulation of interferon-alpha production GO:0032727 9.67 IRF3 IRF7
23 positive regulation of acute inflammatory response GO:0002675 9.67 IL6 IL6ST
24 response to exogenous dsRNA GO:0043330 9.67 IFNA1 IFNA2 IFNB1 IRF3
25 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.66 IRF3 IRF7
26 negative regulation of T cell differentiation GO:0045581 9.64 IFNA2 IFNB1
27 chondroblast differentiation GO:0060591 9.63 FGF2 FGF4
28 negative regulation of T-helper 2 cell cytokine production GO:2000552 9.62 IFNA2 IFNB1
29 regulation of signaling receptor activity GO:0010469 9.61 ADA2 FGF2 FGF4 IFNA1 IFNA2 IFNB1
30 regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000544 9.6 FGF2 FGF4
31 type I interferon biosynthetic process GO:0045351 9.59 IRF3 IRF7
32 MDA-5 signaling pathway GO:0039530 9.58 IRF3 IRF7
33 type I interferon signaling pathway GO:0060337 9.55 IFNA1 IFNA2 IFNB1 IRF3 IRF7
34 cytokine-mediated signaling pathway GO:0019221 9.28 FGF2 ICAM1 IFNA1 IFNA2 IFNB1 IL6
35 positive regulation of transcription by RNA polymerase II GO:0045944 10.15 FGF2 FGF4 IFNB1 IL6 IRF3 IRF7
36 positive regulation of transcription, DNA-templated GO:0045893 10.1 FGF2 IFNA2 IL6 IRF7 PDGFB TP53
37 positive regulation of cell proliferation GO:0008284 10.08 FGF2 FGF4 IL6 IL6ST PDGFB VEGFA
38 positive regulation of gene expression GO:0010628 10.04 FGF4 IL6 PDGFB TP53 VEGFA

Molecular functions related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.67 ADA2 FGF2 FGF4 VEGFA
2 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.61 FGF2 FGF4 PDGFB
3 chemoattractant activity GO:0042056 9.5 FGF2 PDGFB VEGFA
4 platelet-derived growth factor receptor binding GO:0005161 9.48 PDGFB VEGFA
5 C-C chemokine receptor activity GO:0016493 9.46 CCR3 CCR8
6 cytokine receptor binding GO:0005126 9.43 IFNA1 IFNA2 IFNB1
7 cytokine activity GO:0005125 9.43 FGF2 IFNA1 IFNA2 IFNB1 IL6 VEGFA
8 interleukin-6 receptor binding GO:0005138 9.4 IL6 IL6ST
9 type I interferon receptor binding GO:0005132 9.33 IFNA1 IFNA2 IFNB1
10 growth factor activity GO:0008083 9.1 ADA2 FGF2 FGF4 IL6 PDGFB VEGFA

Sources for Kaposi Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....